Medtronic price target raised to $93 from $89 at Truist
Truist raised the firm’s price target on Medtronic (MDT) to $93 from $89 and keeps a Hold rating on the shares after its Q3 earnings beat.
Medscape1d
Medtronic Warns About Insulin Pump Action During Air Travel
In an “urgent medical device correction,” the company urges clinicians to remind patients to monitor their glucose levels during takeoffs and landings.
Medtronic Earnings Review: Stuck In The Single Digits Again
Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.
Medtronic stock down 5% as surgical unit offsets ablation and diabetes growth
Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...
drugdeliverybusiness2d
Medtronic seeks to expand MiniMed 780G label to type 2 diabetes, submits new CGM to FDA
Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...
Medtronic reports third quarter fiscal 2025 financial results
Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025.
drugdeliverybusiness6d
Medtronic warns on air pressure issue with certain MiniMed insulin pumps in Europe
Medtronic (NYSE:MDT) issued an urgent field safety notice in Europe related to multiple versions of its MiniMed insulin pump ...